 Therapeutic effects simvastatin hyperlipidemia CAPD patients causal link hypercholesterolemia due elevated plasma concentrations LDL VLDL remnants CAPD patients effects weeks treatment Simvastatin new HMG coenzyme A-reductase inhibitor mg/day serum lipid lipoprotein A-I concentrations safety parameters subjective side effects patients mean duration CAPD months age years Maximal effects plasma lipoprotein apolipoprotein concentrations weeks stable study Mean plasma cholesterol concentrations mg mg/dl mean LDL-cholesterol concentrations mg mg/dl concentrations g/L g/L data view Simvastatin serious clinical adverse laboratory effects promising drug effective control hyperlipemia large proportion hypercholesterolemic patients cardiovascular morbidity CAPD